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To the Editor 
Melanoma is characterized by increasing trends of incidence and high metastatic potential [1]. The 
transition from non-invasive to invasive and metastatic stage is characterized by a multi-step process by 
which tumour cells acquire the ability to detach and invade adjacent tissues. Loss of the transcription factor 
activator protein-2α (AP-2α) is an important molecular event in melanoma progression resulting in 
deregulation of AP-2 target genes involved in tumour growth and metastasis and associated with short 
Disease-Free-Survival (DFS) [2] and [3]. Our recent investigations on different tumour cells including 
melanoma [4], [5] and [6] provided evidence that not only AP-2α but also AP-2γ play an essential role in 
tumorigenesis by modulating specific genes such as Endothelial and Smooth muscle cell Derived Neuropilin-
like molecule (ESDN) [7]. So far, no data are available regarding AP-2γ and ESDN expression in primary 
melanoma lesions. Therefore, we analysed the expression of these two genes in primary melanomas, to 
understand their relationships as well as their connection with AP-2α expression and melanoma clinico-
pathological features. 
We included 67 patients stage 0 to II (AJCC classification); patients with evidence of metastatic involvement 
at first diagnosis, including positive sentinel lymph node biopsy (SLNB) were excluded. The study was 
approved by the Hospital Ethical Committee. Melanoma samples were subdivided according to Breslow 
thickness based on AJCC classification: 20 in situ and 47 invasive (≤1 mm: 25; >1 – ≤2 mm: 9; >2 – ≤4 mm: 
10; >4 mm: 3). 
All patients with invasive melanomas had regular follow-up visits (median follow-up 4.9 years, range: 1.1–
11.1). One progression localised to regional lymph nodes occurred in a patient with melanoma <1 mm not 
previously treated by SLNB; 13 progressions occurred in patients with melanoma >1 mm (6 nodes, 5 “in 
transit” and 2 distant). Four out of 6 patients developed nodal recurrence in the same basin of previously 
negative SLNB (“false-negative”) and 2 in another regional basin. 
 
AP-2α, AP-2γ and ESDN expression was analysed immunohistochemically on paraffin tumour sections (AP-
2α, C-18; 1:150; Santa Cruz; DCBLD2-ESDN, 1:50; Sigma; AP-2γ, 1:50; Bioworld Technology). The number of 
positive melanoma cells were scored in two categories: score 0 ≤ 30% or score 1 > 30% positive nuclei. 
Univariate/multivariate logistic regression were used to evaluate the significance of the predictor variables’ 
association with DFS. In situ melanomas were excluded from DFS analyses. 
Significant differences were found for marker expression according to tumor thickness. In situ melanomas 
had a high expression of all markers. In invasive melanomas, a progressive down-regulation of AP-2α, AP-2γ 
and ESDN expression was observed, which inversely correlated with increase thickness. Indeed, the large 
majority of thin melanomas (≤1 mm) expressed the three markers on more than 30% of tumour cells (AP-
2α: 22/2; AP-2γ: 21/25; ESDN: 22/25); on the contrary, the majority of thick melanomas showed 
significantly lower AP-2α, AP-2γ and ESDN expression (χ2: p = 0.022 for AP-2α, p < 0.001 for AP-2γ and p < 
0.001 for ESDN). ( Table 1) AP-2α, AP-2γ and ESDN expression was also related to other histopathological 
unfavourable features. Univariate logistic regression showed that a low expression of AP-2α, AP-2γ and 
ESDN was associated with increased vascularity (odds-ratio (OR) 5.77 for AP-2α, 5.14 for AP-2γ and 3.14 for 
ESDN expression <30% positive melanoma cells), vascular invasion (OR 12.8 for AP-2α, 17.34 for ESDN and 
52.8 for AP-2γ) and mitotic rate (OR 16.33 for AP-2α, 17.9 for AP-2γ and 14.64 for ESDN expression). 
 
Table 1. AP-2α, AP-2γ and ESDN expression in primary melanoma and skin metastasis. 
   
 
Univariate analyses showed that a shorter DFS is associated with a low expression of AP-2α (5-year DFS 
33.3% vs 90.9%, p < 0.001), AP-2γ (57.9% vs 85.6%, p = 0.0233) and ESDN (57.4% vs 85.6%, p = 0.0298) ( Fig. 
1). The Hazard Rate (HR) was 10.00 for AP-2α (p = 0.0006), 3.65 for AP-2γ (p = 0.0351) and 3.44 for ESDN 
<30% positive cells (p = 0.0439). 
 
 
 
 
 
Fig. 1.  Correlation of AP-2α (A), AP-2γ (B) and ESDN (C) expression with disease free survival (DFS) in 
primary melanoma lesions. 
 
 
 
To support the relationship between AP-2 family/ESDN down-regulation and melanoma metastatic 
potentialities, we investigated the expression of these markers in 10 archival specimens from skin 
melanoma metastases, 5 corresponding to patients included in the study who developed “in transit” 
localisations and 5 from other unrelated cases. A low expression of AP-2α, AP-2γ and ESDN was observed in 
the majority of cases (Table 1). 
Conflicting data are reported for AP-2α, AP-2γ and ESDN expression in other cancers. In colorectal 
carcinoma, cytoplasmic AP-2α expression was reduced in advanced Dukes's stage tumours whilst AP-2α 
and AP-2γ were inversely related to histological grade [8]. Low AP-2 expression was associated with disease 
progression in breast cancer [9]. ESDN was up-regulated in the highly metastatic compared with parental 
cells in lung cancer [7], whereas a study on gastric cancer correlated loss of ESDN expression with increased 
tumour proliferation [10]. The mechanism of ESDN expression is still poorly understood. We previously 
identified a direct relationship between AP-2 family and ESDN regulation in both vitro and animal 
melanomas [4], providing evidences that AP-2α/AP-2γ regulate tumour growth, chemotherapy induced cell 
death, as well as migration and invasion via specific genetic programs. Furthermore, the analysis of gene 
expression in HeLa cells lacking AP-2α demonstrated that ESDN was among the major candidates for this 
molecular mechanism [4]. 
The concomitant loss of AP-2α, AP-2γ and ESDN in primary melanoma supports preliminary evidence about 
ESDN regulation by the AP-2 family in human melanomas, suggesting a modulation between these genes 
and thus confirming our previous findings [4] and [5]. The relevance of these alterations in the metastatic 
pathways is underlined by the skin metastasis pattern expression. 
In conclusion, despite the relatively low number of patients, this study demonstrates for the first time that 
ESDN and AP-2γ expression is lower in thick melanomas, it is associated with unfavourable histo-
pathological parameters (increased vascularity, vascular invasion and mitoses) and correlates with a shorter 
DFS like for AP-2α. 
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